Lack of awareness, limited sites hinder CAR-T trials for younger patients with cancer

The FDA’s approval of tisagenlecleucel in 2017 resulted in an explosion of research into chimeric antigen receptor T-cell therapies.
However, much of this research has focused on adults.
Data from clincialtrials.gov show more than 200 early phase or phase 1 clinical trials of CAR T-cell therapies are enrolling patients in the United States; however, fewer than 40 of these trials accept patients aged younger than 18 years. In addition, the CAR-T trials open to these younger patients are located in only 17 states and the District of Columbia.
There is an inherent inequity in access to early

The FDA’s approval of tisagenlecleucel in 2017 resulted in an explosion of research into chimeric antigen receptor T-cell therapies.
However, much of this research has focused on adults.
Data from clincialtrials.gov show more than 200 early phase or phase 1 clinical trials of CAR T-cell therapies are enrolling patients in the United States; however, fewer than 40 of these trials accept patients aged younger than 18 years. In addition, the CAR-T trials open to these younger patients are located in only 17 states and the District of Columbia.
There is an inherent inequity in access to early